Metspot XL 50 Tablet is a once-daily extended-release formulation of metoprolol succinate, a beta1-selective adrenoceptor antagonist indicated for the treatment of hypertension, angina pectoris, and heart failure. This tablet is designed to provide a prolonged therapeutic effect, with a slow and controlled release of the active ingredient over a 24-hour period. The recommended starting dose is 25-50 mg once daily, which may be titrated upward to achieve the desired therapeutic effect. Metspot XL 50 Tablet is contraindicated in patients with known hypersensitivity to metoprolol or other beta-blockers, and caution should be exercised in patients with bronchospastic disease, peripheral vascular disease, and those taking non-steroidal anti-inflammatory drugs (NSAIDs) or warfarin. Common side effects include dizziness, fatigue, and cold-like symptoms. Metspot XL 50 Tablet should be used with caution in patients with impaired renal function, liver disease, and thyroid disease, and the dosage should be adjusted according to the patient's creatinine clearance.